ENDRA Life Sciences Inc.

Equities

NDRA

US29273B3024

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-24 pm EDT 5-day change 1st Jan Change
0.2599 USD +2.16% Intraday chart for ENDRA Life Sciences Inc. +12.61% -87.74%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : ENDRA Life Sciences Inc., Q4 2023 Earnings Call, Mar 28, 2024
ENDRA Life Sciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
ENDRA Life Sciences Inc. Welcomes the Adoption of the ICD-10 K76.0 Code for the Diagnosis of Non-Alcoholic Fatty Liver Disease CI
Transcript : ENDRA Life Sciences Inc., Q3 2023 Earnings Call, Nov 14, 2023
ENDRA Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Top Premarket Decliners MT
Transcript : ENDRA Life Sciences Inc., H1 2023 Earnings Call, Aug 14, 2023
ENDRA Life Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
ENDRA Life Sciences Submits De Novo Request for its TAEUS System Liver Fat Application to the U.S. FDA CI
Certain Options of ENDRA Life Sciences Inc. are subject to a Lock-Up Agreement Ending on 27-JUL-2023. CI
Certain Convertible Preferred Stock of ENDRA Life Sciences Inc. are subject to a Lock-Up Agreement Ending on 27-JUL-2023. CI
Certain Warrants of ENDRA Life Sciences Inc. are subject to a Lock-Up Agreement Ending on 27-JUL-2023. CI
Certain Common Stock of ENDRA Life Sciences Inc. are subject to a Lock-Up Agreement Ending on 27-JUL-2023. CI
ENDRA Life Sciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Transcript : ENDRA Life Sciences Inc., Q1 2023 Earnings Call, May 15, 2023
ENDRA Life Sciences Prices Public Offering of Shares, Warrants for Net Proceeds of $3.9 Million MT
US Futures Point Lower Amid Earnings, Ahead of Personal Income, Outlays Report MT
Top Premarket Decliners MT
ENDRA Life Sciences Inc. Auditor Raises 'Going Concern' Doubt CI
Transcript : ENDRA Life Sciences Inc., Q4 2022 Earnings Call, Mar 14, 2023
ENDRA Life Sciences Inc. Announces Resignation of Renaud Maloberti as Chief Commercial Officer, Effective January 13, 2023 CI
ENDRA Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Transcript : ENDRA Life Sciences Inc., Q3 2022 Earnings Call, Nov 14, 2022
Endra Life Sciences Says de Novo Application for TAEUS Monitor Due in 'Coming Weeks' MT
ENDRA Life Sciences Inc. Plans to Submit De Novo Request to U.S. FDA for Its TAEUS System CI
Chart ENDRA Life Sciences Inc.
More charts
ENDRA Life Sciences Inc. is developing an enhanced ultrasound technology platform - Thermo Acoustic Enhanced Ultrasound (TAEUS), a technology which characterizes tissue similar to a magnetic resonance imaging (MRI). The Company's TAEUS technology uses radio frequency (RF) pulses to stimulate tissues, using a small fraction (less than 1%) of the amount of energy that would be transmitted into the body during an MRI scan. The use of RF energy allows its TAEUS technology to penetrate deep into tissue, enabling the imaging of human anatomy at depths equivalent to those of conventional ultrasound. The RF pulses are absorbed by tissue and converted into ultrasound signals. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease (SLD), a chronic liver disease spectrum. It is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.2599 USD
Average target price
11 USD
Spread / Average Target
+4,132.40%
Consensus
  1. Stock Market
  2. Equities
  3. NDRA Stock
  4. News ENDRA Life Sciences Inc.
  5. Endra Life Sciences : Names Senior Director of Finance To Succeed CFO